rs201106410

Variant summary

Our verdict is Benign. The variant received -16 ACMG points: 0P and 16B. BP4_StrongBP6_Very_StrongBS2

The NM_001492.6(GDF1):​c.-873C>T variant causes a 5 prime UTR premature start codon gain change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00182 in 1,613,398 control chromosomes in the GnomAD database, including 4 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).

Frequency

Genomes: 𝑓 0.0013 ( 0 hom., cov: 31)
Exomes 𝑓: 0.0019 ( 4 hom. )

Consequence

GDF1
NM_001492.6 5_prime_UTR_premature_start_codon_gain

Scores

2

Clinical Significance

Benign/Likely benign criteria provided, multiple submitters, no conflicts B:2

Conservation

PhyloP100: -1.97

Publications

0 publications found
Variant links:
Genes affected
GDF1 (HGNC:4214): (growth differentiation factor 1) This gene encodes a secreted ligand of the TGF-beta (transforming growth factor-beta) superfamily of proteins. Ligands of this family bind various TGF-beta receptors leading to recruitment and activation of SMAD family transcription factors that regulate gene expression. The encoded preproprotein is proteolytically processed to generate each subunit of the disulfide-linked homodimer. Studies in rodents suggest that this protein is involved in the establishment of left-right asymmetry in early embryogenesis and in neural development in later embryogenesis. The encoded protein is translated from a bicistronic mRNA that also encodes ceramide synthase 1. Mutations in this gene are associated with several congenital cardiovascular malformations. [provided by RefSeq, Jul 2016]
CERS1 (HGNC:14253): (ceramide synthase 1) This gene encodes a ceramide synthase enzyme, which catalyzes the synthesis of ceramide, the hydrophobic moiety of sphingolipids. The encoded enzyme synthesizes 18-carbon (C18) ceramide in brain neurons. Elevated expression of this gene may be associated with increased longevity, while decreased expression of this gene may be associated with myoclonus epilepsy with dementia in human patients. This protein is transcribed from a monocistronic mRNA as well as a bicistronic mRNA, which also encodes growth differentiation factor 1. [provided by RefSeq, Jul 2016]
CERS1 Gene-Disease associations (from GenCC):
  • progressive myoclonic epilepsy type 8
    Inheritance: AR Classification: STRONG, SUPPORTIVE, LIMITED Submitted by: Ambry Genetics, Orphanet, Labcorp Genetics (formerly Invitae)

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -16 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.77).
BP6
Variant 19-18884227-G-A is Benign according to our data. Variant chr19-18884227-G-A is described in ClinVar as Benign/Likely_benign. ClinVar VariationId is 475372.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BS2
High Homozygotes in GnomAdExome4 at 4 AD,AR,Unknown gene

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
GDF1NM_001492.6 linkc.-873C>T 5_prime_UTR_premature_start_codon_gain_variant Exon 3 of 8 ENST00000247005.8 NP_001483.3 P27539A0A024R7N8
CERS1NM_021267.5 linkc.450C>T p.Ala150Ala synonymous_variant Exon 3 of 8 ENST00000623882.4 NP_067090.1 P27544-1
GDF1NM_001492.6 linkc.-873C>T 5_prime_UTR_variant Exon 3 of 8 ENST00000247005.8 NP_001483.3 P27539A0A024R7N8

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
GDF1ENST00000247005.8 linkc.-873C>T 5_prime_UTR_premature_start_codon_gain_variant Exon 3 of 8 1 NM_001492.6 ENSP00000247005.5 P27539
CERS1ENST00000623882.4 linkc.450C>T p.Ala150Ala synonymous_variant Exon 3 of 8 1 NM_021267.5 ENSP00000485308.1 P27544-1
GDF1ENST00000247005.8 linkc.-873C>T 5_prime_UTR_variant Exon 3 of 8 1 NM_001492.6 ENSP00000247005.5 P27539

Frequencies

GnomAD3 genomes
AF:
0.00130
AC:
198
AN:
151998
Hom.:
0
Cov.:
31
show subpopulations
Gnomad AFR
AF:
0.000363
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00269
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.000830
Gnomad FIN
AF:
0.000472
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00188
Gnomad OTH
AF:
0.00239
GnomAD2 exomes
AF:
0.00117
AC:
287
AN:
245376
AF XY:
0.00112
show subpopulations
Gnomad AFR exome
AF:
0.000389
Gnomad AMR exome
AF:
0.00232
Gnomad ASJ exome
AF:
0.0000998
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.000426
Gnomad NFE exome
AF:
0.00149
Gnomad OTH exome
AF:
0.00133
GnomAD4 exome
AF:
0.00188
AC:
2740
AN:
1461282
Hom.:
4
Cov.:
31
AF XY:
0.00180
AC XY:
1308
AN XY:
726920
show subpopulations
African (AFR)
AF:
0.000448
AC:
15
AN:
33478
American (AMR)
AF:
0.00248
AC:
111
AN:
44708
Ashkenazi Jewish (ASJ)
AF:
0.0000383
AC:
1
AN:
26128
East Asian (EAS)
AF:
0.00
AC:
0
AN:
39690
South Asian (SAS)
AF:
0.000510
AC:
44
AN:
86212
European-Finnish (FIN)
AF:
0.000339
AC:
18
AN:
53174
Middle Eastern (MID)
AF:
0.000347
AC:
2
AN:
5768
European-Non Finnish (NFE)
AF:
0.00222
AC:
2469
AN:
1111770
Other (OTH)
AF:
0.00133
AC:
80
AN:
60354
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.472
Heterozygous variant carriers
0
152
303
455
606
758
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
104
208
312
416
520
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.00131
AC:
199
AN:
152116
Hom.:
0
Cov.:
31
AF XY:
0.00128
AC XY:
95
AN XY:
74378
show subpopulations
African (AFR)
AF:
0.000386
AC:
16
AN:
41498
American (AMR)
AF:
0.00269
AC:
41
AN:
15250
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3472
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5168
South Asian (SAS)
AF:
0.000831
AC:
4
AN:
4814
European-Finnish (FIN)
AF:
0.000472
AC:
5
AN:
10588
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
0.00188
AC:
128
AN:
68010
Other (OTH)
AF:
0.00237
AC:
5
AN:
2110
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.496
Heterozygous variant carriers
0
9
19
28
38
47
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
4
8
12
16
20
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00110
Hom.:
0
Bravo
AF:
0.00150
Asia WGS
AF:
0.000866
AC:
3
AN:
3478
EpiCase
AF:
0.00191
EpiControl
AF:
0.00148

ClinVar

Significance: Benign/Likely benign
Submissions summary: Benign:2
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Benign:1
Jul 01, 2022
CeGaT Center for Human Genetics Tuebingen
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

CERS1: BP4, BP7 -

Progressive myoclonic epilepsy type 8 Benign:1
Jan 06, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.77
CADD
Benign
0.95
DANN
Benign
0.91
PhyloP100
-2.0
PromoterAI
0.0019
Neutral
Mutation Taster
=296/4
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs201106410; hg19: chr19-18995036; COSMIC: COSV55928325; COSMIC: COSV55928325; API